American Journal of Clinical Dermatology

, Volume 17, Issue 6, pp 625–634

Primary and Secondary Chemoprevention of Malignant Melanoma

  • Jessica Mounessa
  • Talayesa Buntinx-Krieg
  • Rosie Qin
  • Cory A. Dunnick
  • Robert P. Dellavalle
Review Article

DOI: 10.1007/s40257-016-0221-5

Cite this article as:
Mounessa, J., Buntinx-Krieg, T., Qin, R. et al. Am J Clin Dermatol (2016) 17: 625. doi:10.1007/s40257-016-0221-5

Abstract

The incidence of malignant melanoma (MM) continues to rise in the United States. While sun protection and full body skin examinations remain the mainstay of preventative care, chemoprevention of the deadly disease has become an increasingly popular field of study. In this focused review, we discuss current findings and analyze the risks and benefits of various agents investigated for the primary and secondary chemoprevention of MM. Such agents include topical retinoids, vitamins, and supplements, Polypodium leucotomas extracts, non-steroidal anti-inflammatory agents (NSAIDs), statins, sunscreens, and field therapy with topical imiquimod for primary and secondary chemoprevention. We further identify a need for expanded high quality human research on the topic.

Copyright information

© Springer International Publishing Switzerland (Outside the USA) 2016

Authors and Affiliations

  • Jessica Mounessa
    • 1
    • 2
  • Talayesa Buntinx-Krieg
    • 3
  • Rosie Qin
    • 4
  • Cory A. Dunnick
    • 2
    • 5
  • Robert P. Dellavalle
    • 2
    • 5
  1. 1.Stony Brook University School of MedicineStony BrookUSA
  2. 2.Department of DermatologyUniversity of Colorado HospitalAuroraUSA
  3. 3.University of Central Florida College of MedicineOrlandoUSA
  4. 4.Department of MedicineUniversity of San DiegoLa JollaUSA
  5. 5.Department of DermatologyDenver VA Medical CenterDenverUSA

Personalised recommendations